175 related articles for article (PubMed ID: 38251678)
21. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
22. Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers.
Sankar K; Pearson AN; Worlikar T; Perricone MD; Holcomb EA; Mendiratta-Lala M; Xu Z; Bhowmick N; Green MD
Transl Gastroenterol Hepatol; 2023; 8():29. PubMed ID: 37601739
[TBL] [Abstract][Full Text] [Related]
23. Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors.
Tolba MF
Int J Cancer; 2020 Dec; 147(11):2996-3006. PubMed ID: 32415713
[TBL] [Abstract][Full Text] [Related]
24. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
25. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Botticelli A; Cirillo A; Scagnoli S; Cerbelli B; Strigari L; Cortellini A; Pizzuti L; Vici P; De Galitiis F; Di Pietro FR; Cerbelli E; Ghidini M; D'Amati G; Della Rocca C; Mezi S; Gelibter A; Giusti R; Cortesi E; Ascierto PA; Nuti M; Marchetti P
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32353934
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review.
Aoki S; Yamashita H; Abe O; Nakagawa K
Transl Cancer Res; 2020 Aug; 9(8):5087-5095. PubMed ID: 35117874
[TBL] [Abstract][Full Text] [Related]
27. Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases.
He K; Barsoumian HB; Bertolet G; Verma V; Leuschner C; Koay EJ; Ludmir EB; Hsu E; Pisipati E; Voss TA; Puebla-Osorio N; Cortez MA; Welsh JW
Front Immunol; 2021; 12():812210. PubMed ID: 34975924
[TBL] [Abstract][Full Text] [Related]
28. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
29. Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.
Liu C; Wang M; Xu C; Li B; Chen J; Chen J; Wang Z
J Immunol Res; 2021; 2021():8970173. PubMed ID: 34877360
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
31. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).
Li M; Hou X; Sai K; Wu L; Chen J; Zhang B; Wang N; Wu L; Zheng H; Zhang J; Mou Y; Chen L
Oncoimmunology; 2022; 11(1):2059874. PubMed ID: 35402080
[TBL] [Abstract][Full Text] [Related]
32. VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.
Zhao Y; Guo S; Deng J; Shen J; Du F; Wu X; Chen Y; Li M; Chen M; Li X; Li W; Gu L; Sun Y; Wen Q; Li J; Xiao Z
Int J Biol Sci; 2022; 18(9):3845-3858. PubMed ID: 35813484
[TBL] [Abstract][Full Text] [Related]
33. Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape.
Ma Y; Guo C; Wang X; Wei X; Ma J
J Exp Clin Cancer Res; 2023 Sep; 42(1):237. PubMed ID: 37697332
[TBL] [Abstract][Full Text] [Related]
34. Role of T cells in liver metastasis.
Wu K; Zhang G; Shen C; Zhu L; Yu C; Sartorius K; Ding W; Jiang Y; Lu Y
Cell Death Dis; 2024 May; 15(5):341. PubMed ID: 38755133
[TBL] [Abstract][Full Text] [Related]
35. Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.
Minami Y; Nishida N; Kudo M
Eur Radiol; 2019 Sep; 29(9):5045-5051. PubMed ID: 30963271
[TBL] [Abstract][Full Text] [Related]
36. Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers.
Shi F; Huang X; Hong Z; Lu N; Huang X; Liu L; Liang T; Bai X
Cancer Lett; 2023 May; 562():216167. PubMed ID: 37031916
[TBL] [Abstract][Full Text] [Related]
37. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
38. Emerging principles of brain immunology and immune checkpoint blockade in brain metastases.
Fares J; Ulasov I; Timashev P; Lesniak MS
Brain; 2021 May; 144(4):1046-1066. PubMed ID: 33893488
[TBL] [Abstract][Full Text] [Related]
39. Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.
Osborne N; Sundseth R; Gay MD; Cao H; Tucker RD; Nadella S; Wang S; Liu X; Kroemer A; Sutton L; Cato A; Smith JP
Am J Physiol Gastrointest Liver Physiol; 2019 Nov; 317(5):G682-G693. PubMed ID: 31433212
[TBL] [Abstract][Full Text] [Related]
40. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]